Acetate supplement research could lead to new ways to treat anemia
10/01/2014
UT Southwestern Medical Center researchers seeking novel treatments for anemia found that giving acetate, the major component of household vinegar, to anemic mice stimulated the formation of new red...
Lungs from donors who die from drowning, asphyxiation may be safe for transplant
10/01/2014
Researchers claim transplanting lungs from donors who die from drowning or asphyxiation appears to be safe and may be a way of 'expanding the donor pool.'
For patients with cervical cancer that has recurred after treatment or has spread elsewhere in the body, adding the experimental drug cediranib to standard chemotherapy improves tumour shrinkage and...
Discovery of shining cells responsible for developing tumors
10/01/2014
This finding will help to track the origin of chemical resistance and to launch personalized medicine by means of developing novel therapies against these cancer stem cellsTumours are mosaics of...
Medicare law aimed a reducing chemotherapy cost turned out to have little impact
10/01/2014
Legislation passed in 2003 to slow the spiraling costs of drugs paid for by the federal government to treat Medicare patients has had no meaningful impact on cancer chemotherapy drug costs, say a...
Study examines medical professional liability claims related to esophageal cancer screening
9/30/2014
An analysis of liability claims related to esophageal cancer screening finds that the risks of claims arising from acts of commission (complications from screening procedure) as well as acts of...
Data from the final analysis of the Phase 3 study COU-AA-302 have shown that Zytiga® (abiraterone acetate) plus low dose prednisolone significantly prolongs overall survival (OS) with a median...
The monoclonal antibody nivolumab achieves superior response rates and a longer duration of response than standard chemotherapy[1] in patients whose melanoma has progressed after treatment with...
Melanoma drug combo improves patient survival rate, decreases risk of harsh side effect
9/30/2014
A UCLA researcher at the Jonsson Comprehensive Cancer Center helped pioneer a new therapy that combines the drug Zelboraf® with an experimental drug cobimetinib, allowing metastatic melanoma...
Updated data from the ongoing AURA study of AZD9291 shows encouraging, although still immature, median progression free survival of 9.6 months (95% CI 8.